Thomas Jefferson, MD
General Practice · Little Rock, ARNPI 1790891448
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 84.7% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $6,306 and has fallen 96.6% since, to $216 in 2025. Among general practice clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $66.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$11K
- Viiv Healthcare Company$861
- Indivior Inc.$238
- Theratechnologies Inc.$217
- AbbVie$94
- Johnson & Johnson$94
- plus $443 from 13 others
Across 3 payments — averaging $4142.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$10K
- Merck$3K
What the payments were for
- Consulting fees$7,15056%
- Travel & lodging$2,12217%
- Food & beverage$3,49627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 78 | $10,821 |
| Viiv Healthcare Company | 57 | $861 |
| Indivior Inc. | 10 | $238 |
| Theratechnologies Inc. | 11 | $217 |
| AbbVie | 5 | $94 |
| Johnson & Johnson | 6 | $94 |
| EMD Serono, Inc. | 3 | $66 |
| Braeburn Inc. | 3 | $60 |
| Alkermes, Inc. | 2 | $55 |
| Orexo US, Inc. | 3 | $46 |
| Antares Pharma, Inc. | 2 | $43 |
| Merck | 3 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $31 |
| Redhill Biopharma Inc. | 1 | $26 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Myovant Sciences Inc. | 1 | $12 |
How this compares
$12,768 in reported general payments places this provider in the 95th percentile of 720 general practice providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 214 | $859,387 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 25 | $94,175 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 133 | $30,444 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 12 | $29,182 |
| DescovyEmtricitabine/Tenofov Alafenam | 14 | $29,157 |
| OzempicSemaglutide | 19 | $18,661 |
| EliquisApixaban | 30 | $17,348 |
| Buprenorphine Hcl | 177 | $8,581 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $7,641 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,334 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,836 |
| Megestrol Acetate | 16 | $6,016 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $1,747 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 46 | $1,273 |
| Gabapentin | 100 | $1,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $10,821 | $888,544228 claims |
| Viiv Healthcare CompanyTriumeq | $861 | $94,17525 claims |
| Indivior Inc.Suboxone | $238 | $7,64111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 720 general practice providers in Arkansas.
Other general practice in Little Rock
- Samuel StrongLittle Rock$27K
- Tina NicholsLittle Rock$8K
- Samaria MascagniLittle Rock$7K
- David ReynoldsLittle Rock$3K
- Ashley McMillanLittle Rock$3K
- Ethan AkeLittle Rock$3K
- Roy HinsonLittle Rock$2K
- Ann MeadorLittle Rock$2K
- Stephen BannermanLittle Rock$2K
- Ned AlleyLittle Rock$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.